A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

This study is testing AK104 — a bispecific antibody that blocks two immune checkpoint proteins at once (PD-1 and CTLA-4) — as a maintenance treatment in patients with stage III non-small cell lung cancer (NSCLC) that cannot be surgically removed. AK104 is given after standard chemoradiotherapy to try to prevent the cancer from coming back. **You may be eligible if...** - You are 18 or older - You have been confirmed to have stage III NSCLC that cannot be surgically removed - Your tumor does not have EGFR mutations or ALK/ROS1 fusions - You completed chemoradiotherapy 1 to 42 days before starting treatment - Your cancer did not progress after completing chemoradiotherapy - You received the right radiation dose (around 60 Gy) - You are in good general health (ECOG score 0–1) and have adequate organ function **You may NOT be eligible if...** - Your cancer has EGFR mutations or ALK/ROS1 gene fusions - Your cancer progressed after chemoradiotherapy - You have active autoimmune disease or serious lung inflammation Talk to your doctor to see if this trial is right for you.